Literature DB >> 29057512

Induction of porcine-specific regulatory T cells with high specificity and expression of IL-10 and TGF-β1 using baboon-derived tolerogenic dendritic cells.

Mingqian Li1,2, Judith Eckl3,4, Jan-Michael Abicht5,6, Tanja Mayr5,6, Bruno Reichart6, Dolores J Schendel3,4, Heike Pohla1,2,3.   

Abstract

BACKGROUND: Regulatory T cells (Treg) play an important role in maintenance of homeostasis in vivo. Treg application to alleviate allo-organ rejection is being studied extensively. However, natural Treg (nTreg) expansion in vitro is laborious and expensive. Antigen-specific Treg are more effective and require lower cell numbers than use of nTreg for immune control. The baboon, as a non-human primate experimental animal model, is widely used in xenotransplantation research. An effective method to generate baboon xeno-specific Treg would benefit research on immune tolerance in xenotransplantation using this model system.
METHOD: Baboon tolerogenic dendritic cells (tolDC) were generated in 3 days from monocytes isolated from baboon peripheral blood mononuclear cells in medium supplemented with anti-inflammatory cytokines. After loading with porcine-specific (PS) in vitro-transcribed RNA (ivtRNA), tolDC were used to induce CD4+ T cells to become porcine-specific Treg (PSTreg) in cocultures supplemented with IL-2 and rapamycin for 10 days. Anti-inflammatory and inflammatory cytokine expression was evaluated at the mRNA and protein levels in both baboon tolDC and PSTreg. Functional assays, suppression of activation markers on porcine-specific effector T cells (PSTeff) and inhibition of PSTeff proliferation, were used to test PSTreg specificity.
RESULTS: TolDC generated with this method exhibited a tolerogenic phenotype, expressed CCR7 and produced high levels of IL-10 and TGF-β1, whereas IL-12p40 and IFN-γ were not expressed. PSTreg were successfully generated in cocultures of CD4+ T cells and PS ivtRNA-loaded tolDC. They exhibited a CD3+  CD4+  CD25+  CD127low/-  CD45RAlow  Foxp3+ phenotype and were characterized by high expression of IL-10 and TGF-β1 mRNA and protein. They showed upregulated expression of EBI3 and GARP mRNA. PSTreg exhibited highly suppressive effects toward PSTeff, secreting high amounts of IL-10 and TGF-β1 cytokine upon interaction with PSTeff and suppressing IFN-γ expression on PSTeff.
CONCLUSION: In this study, a fast 3-day method to generate baboon-derived tolDC is provided that allows subsequent induction of PSTreg displaying high porcine-antigen specificity and expression of IL-10 and TGF-β1. Porcine-specific baboon Treg can be used in porcine solid organ or cell xenotransplantation studies through adoptive cell transfer into host baboons.
© 2017 The Authors. Xenotransplantation Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-10; IL-27; IL-35; TGF-β; baboon dendritic cells; baboon regulatory T cells; immune tolerance; xenotransplantation

Mesh:

Substances:

Year:  2017        PMID: 29057512     DOI: 10.1111/xen.12355

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  3 in total

Review 1.  Xenotransplantation: A New Era.

Authors:  Amber N Carrier; Anjali Verma; Muhammad Mohiuddin; Manuel Pascual; Yannick D Muller; Alban Longchamp; Chandra Bhati; Leo H Buhler; Daniel G Maluf; Raphael P H Meier
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

2.  The contribution of neuropilin-1 in the stability of CD4+ CD25+ regulatory T cells through the TGF-β1/Smads signaling pathway in the presence of lipopolysaccharides.

Authors:  Yulei Gao; Xiang Zhang; Ziyi Wang; Yuting Qiu; Yancun Liu; Songtao Shou; Yanfen Chai
Journal:  Immun Inflamm Dis       Date:  2021-11-10

3.  Adoptive transfer of xenoantigen‑stimulated T cell receptor Vβ‑restricted human regulatory T cells prevents porcine islet xenograft rejection in humanized mice.

Authors:  Xi Jin; Min Hu; Lina Gong; Huifang Li; Yan Wang; Ming Ji; Hong Li
Journal:  Mol Med Rep       Date:  2018-09-10       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.